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Abstract
Patients with chronic hepatitis C virus (HCV) infection and disease-related
complications – among them cirrhosis and liver failure – pose a particular
management challenge. Some of these patients may fail to respond to current
therapy (non-responders), and some are affected so severely that treatment puts
them at an unacceptable risk for complications. Treatment with pegylated
interferon (peg-IFN) plus ribavirin improves hepatic enzyme levels and eradicates
the virus in   50% of patients; however, a signiﬁcant number of patients do not
respond to therapy or relapse following treatment discontinuation. Several viral,
hepatic and patient-related factors inﬂuence response to IFN therapy; many of
these factors cannot be modiﬁed to improve long-term outcomes. Identifying risk
factors and measuring viral load early in the treatment can help to predict response
to IFN therapy and determine the need to modify or discontinue treatment.
Retreatment options for patients who have failed therapy are limited. Retreatment
with peg-IFN has been successful in some patients who exhibit an inadequate
response to conventional IFN treatment, particularly those who have relapsed.
Consensus IFN, another option in treatment-resistant patients, has demonstrated
efﬁcacy in the retreatment of non-responders and relapsers. Although the optimal
duration of retreatment and the beneﬁts and safety of maintenance therapy have
not been determined, an extended duration is likely needed. This article reviews
the risk factors for HCV treatment resistance and discusses the assessment and
management of difﬁcult-to-treat patients.
As the most common blood-borne pathogen in the
United States, hepatitis C virus (HCV) is an escalating
healthcare concern (1). Approximately 60–85% of
patients acutely infectedwithHCV progressto chronic
disease, deﬁned as the presence of HCV RNA in the
blood for more than 6 months (2). The National
Center for Health Statistics recently estimated that
1.3% of the US population – or 3.2 million people –
have chronic HCV infection (3). The prevalence of
infection is highest among patients aged 40–49 years
(3); as these individuals age and the disease progresses
(Fig. 1) (4), HCV-related complications will become
more evident and severe (3, 4).
Among individuals with chronic HCV infection,
15–20% progress to end-stage liver disease (5).
Cirrhosis and hepatocellular carcinoma, in parti-
cular, are life-threatening complications, with an
estimated 42% of cirrhosis and 48% of liver cancer
cases in the United States, Canada and Cuba attri-
buted to chronic HCV infection (6). HCV-induced
liver disease results in 8000–10000 US deaths each
year (7).
Achieving viral eradication is the goal of antiviral
therapy and is deﬁned by sustained virological re-
sponse (SVR; Table 1) (5, 8). The rates of SVR have
increased with improvements in antiviral therapy. SVR
rates with interferon (IFN) monotherapy are approxi-
mately 6–12%, increasing to 38–42% with conven-
tional IFN and ribavirin (RBV), and increasing as
high as 55% in major clinical trials of pegylated IFN
(peg-IFN) and RBV (9–12). Regardless, the number of
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nued hepatic injury is substantial.
Although some factors that inﬂuence SVR rates, such
as inadequate dosage, inappropriate management of
side effects and earlydose reductions, may be corrected,
others, such as HCV genotype, baseline viral load, race
and age, cannot be speciﬁcally modiﬁed to improve
outcomes (13). Ongoing alcohol and substance abuse
has also been shown to contribute to the failure of IFN-
based treatment (14–16), as well as the development of
hepatocellular carcinoma (17). Identifying the risk
factorsforpoorresponsecanaidcliniciansinpredicting
response and making treatment and retreatment deci-
sions. The patient who does not respond to or who fails
prior therapy and is referred for new treatment options
poses a particular challenge; for example, a patient who
discontinues therapy because of treatment-related ad-
verse effects would have to be carefully evaluated before
starting subsequent IFN-based retreatment, especially
to determine appropriate management of complica-
tions. This article describes viral and host-related risk
factors for poor treatment response to initial IFN
therapy, evaluates current pharmacological options for
the difﬁcult-to-treat HCV-infected population and dis-
cusses methods to predict potential treatment failure.
Viral factors inﬂuencing treatment response
in hepatitis C virus infection
Hepatitis C virus population dynamics
Hepatitis C virus exists as a quasispecies, comprising
closely related variants that are genetically distinct
(18–20). The continuous production of these variants
allows HCV to escape host defences and resist clear-
ance by antiviral therapies (18). Thus, patients who
have minimal HCV complexity (i.e. small quasispecies
sequence) are more likely to achieve SVR than patients
with large HCV complexity and signiﬁcant changes
in the quasispecies composition (18, 21). To further
understand HCV resistance to antiviral therapies,
HCV replicon cell lines were developed with an IFN-
resistant phenotype (22). Namba et al. (22) suggested
that genetic alterations within the cell lines underlie
IFN resistance; however, further research is needed to
explain fully the mechanisms of antiviral resistance in
HCV infection.
Hepatitis C virus genotype
The HCV genotype, in particular, is a primary pre-
dictor of response to IFN therapy. Currently, six major
HCV genotypes with multiple subtypes are character-
ized, and HCV subtypes 1a and 1b are isolated most
often in the United States (23). Unfortunately, chronic
infection with HCV genotype 1 is associated with
greater resistance and lower SVR rates than other
genotypes (21, 24–27). In a study of peg-IFN-a-2a
and RBV, Fried et al. (9) noted that an HCV genotype
other than 1 was an independent and signiﬁcant
predictor of SVR (odds ratio, 3.25; 95% conﬁdence
interval, 2.09–5.12; Po0.001). Nguyen et al. (26) also
found lower SVR rates with IFN-based therapies in US
veterans infected with HCV genotype 1 vs. genotypes
2/3 (13 vs. 61% respectively).
Viral load
Patients with pretreatment high viral loads have worse
long-term outcomes than patients with low loads (24,
28). Evaluating 24-h HCV kinetics, Boulestin et al.
(24) noted a better response to antiviral therapy when
Table 1. Treatment outcomes in hepatitis C management (5, 8)
Treatment outcome Deﬁnition
Non-response o2-log decline in baseline HCV RNA levels after 12 weeks of therapy
Partial response Z2-log decline in serum HCV RNA occurs, but the virus is detectable after 24 weeks of treatment
Sustained virological response HCV RNA remains undetectable in the serum 6 months after therapy is discontinued
Relapse Reappearance of HCV RNA following treatment withdrawal
HCV, hepatitis C virus.
Exposure
Acute infection
Chronic hepatitis C
(≈55–86% of acutely
infected patients)
Spontaneous resolution
(≈25–45% of acutely
infected patients)
Slow
fibrosis progression
Intermediate
fibrosis progression
Rapid
fibrosis progression
Cirrhosis (≈20% of all
patients with chronic
hepatitis C)
Decompensated
liver disease
Hepatocellular carcinoma
(2–5% of patients with
cirrhosis annually)
Death
Alcohol, HIV, and
hepatitis B may
accelerate fibrosis
Fig. 1. Natural history of hepatitis C virus (HCV) infection.
[Reprinted from Postgraduate Medical Journal,L oR oVIII et al.
‘Management of Chronic hepatitis C’ 2005; 81: 378; with
permission from BMJ Publishing Group Ltd (4).]
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ing the ﬁrst 24h of IFN-a-2b therapy, reductions in
viraemia were greater in patients with low viral loads
vs. those with baseline loads Z5.55log10copies/mL
(1.26 0.14 vs. 0.70 0.22 respectively; P=0.016).
These investigators also associated large viral loads
withslowerday1 viral decay, as reductions Z0.5log10/
24h were documented in 82% of patients with base-
line viral levels o5.55log10copies/mL (range of viral
decay: 0.38–1.72log10copies/mL) vs. 45% of patients
with signiﬁcant baseline viraemia (range of viral
decay: 0.09–2.49logcopies/mL) (24). Similarly, Jess-
ner et al. (28) found that responders to peg-IFN-a-2a
plus RBV exhibited lower baseline viraemia vs. non-
responders (P=0.039).
Host factors inﬂuencing treatment response
in hepatitis C virus infection
Fibrosis and cirrhosis
Cirrhosis and cirrhotic liver disease are estimated to
develop in 12.5% of patients with a 20-year history
of hepatitis C (29). Although patients with advanced
ﬁbrosis or early-compensated cirrhosis generally have
lower response rates, they can be successfully treated
and may achieve SVR (30). In a trial of 1311 patients
with advanced liver disease, 63% of all patients and
52% of patients with genotype 1 treated with peg-IFN
plus RBV achieved SVRs (31). However, the success
of antiviral therapy diminishes in the face of decom-
pensated cirrhotic disease owing to the severity of
adverse effects in these severely ill patients (29, 32). In
addition, in a subanalysis of the HALT-C (Hepatitis C
Antiviral Long-term Treatment Against Cirrhosis)
study conducted by Everson et al., the presence of
advanced ﬁbrosis and cirrhosis was a major indepen-
dent predictor of non-response to antiviral therapy.
This study compared four groups of patients with
increasingly severe liver disease, as determined by
Ishak scores and platelet counts. SVR rates decreased
from 23 to 9% as Ishak scores increased and
platelet counts decreased (Po0.0001 for trend),
conﬁrming the effect of advanced liver disease in
antiviral therapy (33).
Race
Hepatitis C virus kinetics and drug pharmacokinetics
are inﬂuenced by select demographical and patient-
speciﬁc characteristics such as race (34). For example,
HCV-infected African American patients are less re-
sponsive to antiviral therapy than the non-Hispanic
white population (35, 36). In 401 patients infected
with HCV genotype 1, peg-IFN-a-2a- and RBV-pro-
duced SVR rates of 28% for African American patients
and 52% for white patients (Po0.0001) (37). Break-
through viraemia (13 vs. 6%; P=0.05) was also more
common among African Americans. Importantly,
rates of serious adverse events, dose reductions and
discontinuations were similar between the groups,
suggesting another mechanism for the observed efﬁ-
cacy difference.
The mechanism behind a lack of response in African
Americans has not been fully elucidated (38). One
possible explanation is a high prevalence of HCV
genotype 1 among African American patients (88–96%)
(36, 39), but this cannot fully explain the insufﬁcient
response. Layden-Almer et al. (38) noted that compared
with white patients, African Americans infected with
genotype 1 exhibited signiﬁcantly lower decreases in
ﬁrst-phase viral RNA (88.6 vs. 98.2% respectively;
P=0.005), slower elimination of infected cells (0.13/day
vs. 0.20/day respectively; P=0.006) and smaller declines
in mean viral RNA over 1 month (1.15log10copies/mL
vs. 3.61logcopies/mL respectively; P=0.001).Thissug-
gests that African Americans may have an impaired
ability to block viral production.
Fontana et al. (40) developed a model to estimate
the probability of severe ﬁbrosis in African American
and white patients based on commonly available
clinical and laboratory parameters. The Ishak ﬁbrosis
scores of 205 for white and 194 for African American
patients were modelled using simple and multiple
logistical regressions. These scores were found to be
equally predictive in both groups of patients and may
be useful in identifying difﬁcult-to-treat patients in the
African American cohort.
Age
In the elderly population (age 465 years), immuno-
logical suppression, chronic disease and concurrent
medications adversely affect response and heighten the
probability of adverse reactions to antiviral therapy.
However, research focusing on the efﬁcacy and safety
of antiviral therapy in the older population is limited
to a few small, single-centre studies (41–43). In a
retrospective cohort study of 84 elderly patients age
Z65 years without genotype 1b or high viral load, 30
patients (35.7%) receiving IFN monotherapy achieved
SVRs (41). Eleven patients (13%) withdrew because of
adverse events, and univariate analysis showed a high-
er likelihood of withdrawal owing to adverse events
among those age 470 years than those age   70
(Po0.009). The likelihood of SVR was signiﬁcantly
lower among those with high baseline viraemia (HCV
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ﬁbrosis (P=0.04) and HCV genotype 1 (41). Thus,
advanced age alone reduces antiviral effectiveness, but
the addition of viral and hepatic risk factors further
worsens response.
Obesity
About 20–37% of HCV-infected patients are obese, a
potential barrier to treatment success (44, 45). The
body mass index inversely correlates with SVR (46),
and serum leptin, which is elevated in obese patients,
is a predictor of antiviral treatment resistance in HCV
infection with low viraemia (47). One of several
explanations developed to explain the interaction
between obesity and antiviral therapy response (46)
focuses on hepatic steatosis, because obesity is an
independent risk factor for fatty liver disease (45, 48,
49). Other explanations include an obesity-triggered
inﬂammatory reaction that decreases response and
impairs IFN absorption owing to high levels of sub-
cutaneous fat (44, 46). Regardless of the cause of lower
response ratesin obese HCV-infected patients(44, 50),
weight loss is an important component of treatment,
as it may lower elevated liver enzymes and improve
liver ﬁbrosis (51). Weight-based dosing of antiviral
medications also becomes an important consideration
in patients with higher body mass indices (52).
Hepatitis C virus/human immunodeﬁciency virus
co-infection
An estimated 1 million individuals are human immu-
nodeﬁciency virus (HIV) positive in the United States
alone, and as many as 300000 are said to be co-
infected with HCV (53). Co-infection is associated
with substantial morbidity and mortality, including
end-stage liver disease, which is the leading cause of
death in the hospitalized HIV population (54).
Human immunodeﬁciency virus co-infection com-
plicates HCV antiviral therapy. Common adverse
effects of IFN and RBV therapy, such as depression
and anaemia, are often ampliﬁed in patients also
receiving antiretroviral therapy (55), and the risk of
drug–drug interactions is substantial. HCV clearance
may be slower in patients co-infected with HIV (56),
and relapse is common among co-infected responders
(57, 58). In a study by Soriano et al. (58) in 89 HIV/
HCV-infected patients, 48 (53.9%) exhibited a nega-
tive plasma HCV RNA at the end of treatment with
peg-IFN-a-2b and RBV, but only 29 (32.6%) achieved
SVRs 6 months after treatment discontinuation. In
another study (55), 133 patients infected with HCV
and HIV were randomly assigned to receive either
peg-IFN-a-2a or standard IFN-a-2a with RBV.
Although the group receiving the peg-IFN regimen
showed higher SVR rates (27 vs. 12%, P=0.03), the
rate was still lower than the rates reported in patients
infected with HCValone (9, 10, 57).
Management of the co-infected patient must be
individualized and should focus on viral suppression
with a peg-IFN regimen (59, 60). As stated above,
HCV progression is likely enhanced in co-infected
patients and, therefore, may justify more aggressive
and earlier therapy. Treatment options include HCV-
speciﬁc regimens, maintenance therapy, alternative
IFN formulations and observation (60). Maintenance
therapy with low-dose peg-IFN may slow progression
of ﬁbrosis, and observation may be an appropriate
option for patients with more mild hepatic histology
(60). An important issue in this population is whether
HCV treatment could enable more extensive use of
retroviral agents. This question will likely be answered
as more co-infected patients are treated successfully
with anti-HCVagents.
Liver transplantation
Graft re-infection in liver transplantation resulting
from chronic HCV infection is common, as the
virus is seeded from the bloodstream to the new graft
(61). Orthotopic liver transplantation affects response
to HCV therapies, with SVR rates of 20–30%
(61–68), which are lower than those achieved in
non-transplantation patients. A meta-analysis of 48
studies examined the safety and efﬁcacy of both
standard IFN and peg-IFN in liver transplant recipi-
ents (69). The overall SVR rates were 24% with IFN
and RBV and 27% with peg-IFN and RBV; disconti-
nuation rates were 24 and 26%, and pooled rates of
graft rejection were 2 and 5% respectively. The slight
efﬁcacy advantage for peg-IFN was attenuated by the
slight disadvantage in the rates of discontinuation and
graft rejections.
Adverse effects also compromise outcomes. Adverse
effects can prompt premature treatment discontinua-
tion in up to 50% of patients (61, 70). Severe neutro-
paenia and the corresponding increased risk of
infection and haemolytic anaemia are primary treat-
ment-limiting toxicities associated with IFN plus RBV
(61, 71). In 34 HCV-infected transplant recipients
treated with peg-IFN-a-2a 180mg/week for 48 weeks,
Chalasani et al. (72) documented an SVR rate of only
12% and awithdrawal rate attributed to adverse effects
of 30%.
Several investigations regarding optimal regimens
for transplant recipients were encouraging (73, 74).
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who did not respond to previous IFN-RBV therapy
found that adding amantadine to IFN and RBV led to
an SVR rate of 33% (73). In another post-transplanta-
tion study, 27 non-responders to recurrent HCV
treatment with IFN and RBV were retreated with peg-
IFN-a-2b and RBV and compared with 21 untreated
patients (74). Only two patients (7%) discontinued
therapy because of adverse effects, and eight patients
(30%) in the intent-to-treat population achieved an
SVR. Interestingly, cyclosporine use (as immunosup-
pressive therapy) was signiﬁcantly associated withviral
clearance (P   0.03). Fibrosis scores determined on
graft biopsy improved in 76% of treated patients and
only 5% of untreated patients. Improvement did not
correlate with SVR; ﬁbrosis scores improved in 65% of
treated patients who did not achieve SVR (74).
Kidney transplantation
Human immunodeﬁciency virus infection complicates
the treatment of kidney transplantation candidates and
graft recipients. Up to 32.1% of patients on mainte-
nance dialysis are anti-HCV positive (75–78), as are
6.8% of adult cadaveric renal graft recipients (79). HCV
infection is an independent risk factor that increases the
risk of death among dialysis patients up to 2.39-fold
(80–82) and increases mortality rates among transplant
recipients(80,81).ChronichepatitisCisalsoassociated
with mixed essential cryoglobulinaemia (83), increasing
post-transplantation morbidity byenhancing the riskof
de novo or recurrent HCV-associated glomerulopathies
(84–88). Recurrence of HCV-associated kidney disease
can adversely affectgraftsurvivaland has been linkedto
higher serum creatinine levels (85, 89).
Data support treating patients who have chronic
hepatitis C and are awaiting kidney transplantation
(90, 91), improving both renal histology and biochem-
ical markers of renal function (90). IFN monotherapy
is the treatment of choice in HCV-positive dialysis
patients awaiting transplantation (92, 93); data are
limited on peg-IFN in dialysis patients (94–97). In
addition, RBV is generally avoided in dialysis pati-
ents, because it may induce haemolytic anaemia (98).
Two meta-analyses found that IFN monotherapy
produced SVR rates of 33–39% (92, 99). RBV may also
be indicated in patients with HCV-related glomerulo-
pathy because it may reduce rates of proteinuria.
Importantly, virological relapse rates are very low in
dialysis patients who achieve an SVR before transplan-
tation (91). Pre-transplantation treatment may also
prevent postoperative complications such as ﬁbrosing
cholestatic hepatitis (91).
Amantadine monotherapy was not efﬁcacious in
treating HCV infection in renal transplantation pa-
tients, showing no effect on HCV viraemia or liver
histology (100). The addition of amantadine to RBV
was also not superior to RBV in renal transplantation
patients with chronic hepatitis C, perhaps because of
the poor tolerability of both medications in patients
with impaired renal function (101).
Routine antiviral therapy for patients after kidney
transplantation is not recommended because of risk of
graft rejection (102–106). Exceptions may include
patients with HCV-associated glomerulonephritides
to prevent graft loss. Patients with advanced ﬁbrosis
may also receive treatment to prevent death from liver-
related complications.
Other factors
Patient non-compliance and incorrect medication
administration may be modiﬁable risk factors for
treatment failure. Illicit drug or alcohol abuse are
associated with non-compliance, and adverse events
prompt treatment discontinuation in up to 14% of
patients receiving peg-IFN regimens (2). The com-
mon, occasional and rare adverse events seen with IFN
and RBVare listed in Table 2 (107). Similarly, psychia-
tric disorders (e.g. depression) present before treat-
ment initiation or resulting from treatment may
compromise compliance and cause early treatment
discontinuation (8, 26).
Treatment of difﬁcult-to-treat human
immunodeﬁciency virus patients
Preventing complications is a prominent considera-
tion in the management of HCV infection, and
aggressive attempts are required to treat patients at
risk for complications. The natural history of the
disease should also be a major factor in deciding on a
course of therapy, as patients with mild or no ﬁbrosis
may not require such aggressive therapy.
Patients exhibiting any of the multiple risk factors,
inﬂuencingresponse to antiviraltherapy,posea challenge
in the management of chronic hepatitis C. Although a
regimen of peg-IFN and RBV is the standard of care,
consensus IFN (CIFN) and RBV also may also be
efﬁcacious in treatment-naı ¨ve patients at risk for poor
response. In an open-label, prospective study by
Sjogren et al. (108), 128 treatment-naı ¨ve patients with
chronic HCV infection were randomized to receive
CIFN 15mg or IFN-a-2b 3MU three times weekly plus
RBV 1000mg/day for 48 weeks. The results showed a
substantial difference in SVR rates: At 72 weeks, 57%
of the CIFN treatment group was HCV RNA negative
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(P=0.052). Subgroup analyses showed signiﬁcantly
higher SVR rates with CIFN in patients with high
baseline HCV RNA (Z800000IU/mL) or HCV geno-
type 1 or both (Table 3). The investigators concluded
that CIFN should be considered for treatment-naı ¨ve
patients, particularly those with high viral loads or
genotype 1 infection (108).
The efﬁcacy of high-dose peg-IFN was evaluated in
the RENEW trial (RE-treatment of Non-responders
with Escalating Weight-based Therapy trial), in which
704 non-responders to IFN plus RBV therapy were
randomized to receive peg-IFN-a-2b 3.0 or 1.5mg/kg/
week plus RBV 12–15mg/kg/day (109). SVRs were
achieved in 17% of the 3.0mg/kg group vs. 12% of the
1.5mg/kg group (P=0.03; intent-to-treat analysis).
Safety and tolerability were similar (115).
Consensus IFN, another option for the retreatment
of chronic HCV infection, is associated with SVR rates
of 26–30% in non-responders and rates as high as 58%
in relapsers (110–112). Cornberg et al. (110) con-
ducted an open-label pilot study of CIFN and RBV in
77 patients who did not respond to standard IFN
regimens (90% of patients had HCV genotype 1).
CIFN was given in an induction dose of 18mg/day for
8 weeks, followed by 9mg/day for 40 weeks or as a
standard dose of 9mg/day for the full 48 weeks. RBV
dose was weight based: 1000mg/day for o75kg or
1200mg/day for 475kg. The SVR rate was 30% (23/
Table 2. Adverse effects of interferon and ribavirin
Interferon
Common (Z10%)
Mild bone marrow suppression (anaemia, leucopaenia,
thrombocytopaenia)
Depression
Insomnia
Fatigue and irritability
Weight loss/anorexia
Fever, myalgia, headaches, and ﬂu-like symptoms
Injection-site irritation
Nausea/vomiting and diarrhoea
Occasional (2–9%)
Retinopathy (usually not clinically signiﬁcant)
Exacerbation of autoimmune condition (e.g. hepatitis,
thyroiditis, rheumatoid arthritis, psoriasis)
Congestive heart failure and arrhythmias
Rare ( 1%)
Severe bone marrow depression
Seizures
Tinnitus and hearing loss
Hyperglycaemia
Renal failure
Pneumonitis
Ribavirin
Common (Z10%)
Haemolytic anaemia (dose dependent)
Fatigue
Rash and pruritis
Nasal stufﬁness
Cough
‘Hepatitis C: a review for primary care physicians’. Adapted from CMAJ;
174: 649–659 by permission from the publisher. r Canadian Medical
Association (107).
Table 3. Sustained response to consensus interferon/ribavirin vs. interferon-a-2b/ribavirin by hepatitis C virus genotype, ethnicity,
gender and body weight
Consensus interferon/ribavirin
(n=63)
interferon-a-2b/ribavirin
(n=65) P-value
All genotypes
o800000IU/mL 12/21 (57%) 14/26 (54%) 0.82
Z800000IU/mL 24/42 (57%) 12/39 (31%) 0.017
Genotype 1
o800000IU/mL 5/13 (38%) 9/20 (45%) 0.70
Z800000IU/mL 13/28 (46%) 4/28 (14%) 0.0089
Genotype-non 1
o800000IU/mL 7/8 (88%) 5/6 (83%) 0.82
Z800000IU/mL 11/14 (79%) 8/11 (73%) 0.70
Race
White 28/42 (67%) 16/40 (40%) 0.015
Non-white 8/21 (38%) 10/25 (40%) 0.89
Sex
Men 19/43 (44%) 17/44 (39%) 0.59
Women 17/20 (85%) 9/21 (43%) 0.005
Weight
o75kg 15/19 (79%) 10/20 (50%) 0.059
Z75kg 21/44 (48%) 16/45 (36%) 0.24
[Adapted with permission of Springer Heidelberg from Digestive Diseases & Sciences; 50: 227–232. r 2005 (108).]
Statistically signiﬁcant.
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non-responders with HCV genotype 1. Surprisingly,
the SVR rate was 28% with the 18/9mg/day induction
regimen but 32% with the 9mg/day regimen. In subset
analyses, investigators noted the greatest response
among patients previously treated with IFN mono-
therapy and the poorest response among those with
liver cirrhosis (Fig. 2) (110).
The DIRECT trial (Daily-Dose Consensus Interfer-
on and Ribavirin: Efﬁcacy of Combined Therapy trial)
was a phase 3, open-label, multicentre study investi-
gating daily CIFN in 343 previous non-responders to
peg-IFN and RBV (113). Patients were randomized to
receive either CIFN 9mg/dayandRBV(1000–1200mg/
day) or CIFN 15mg/day and RBV. The majority of
patients had evidence of bridging ﬁbrosis or cirrhosis
on biopsy, and the mean washout period was 485–535
days. Viral response rates at week 48 were 16%
[transcription-mediated ampliﬁcation (TMA) assay]
and 22% [branched DNA (bDNA) assay] for patients
receiving CIFN 9mg, and 19% (TMA) and 25%
(bDNA) for those receiving CIFN 15mg. Viral response
was lower in patients with higher ﬁbrosis scores.
Among patients receiving CIFN 9mg, end-of-treatment
responses were noted in 19% with ﬁbrosis scores of
F0–F2 (TMA), 16% with F3 and 8% with F4. Among
patients receiving CIFN 15mg/day, end-of-treatment
responses were noted in 28, 19 and 6% of patients
respectively. The end-of-treatment response rate was
lower for patients who underwent longer washout
periods. The effect of ﬁbrosis score and washout period
in this study may require further investigation.
Treatment duration is critical in complicated chronic
hepatitis C infection. A peg-IFN plus RBV regimen
should be continued for 24 weeks in treatment-naı ¨ve
patients infected with HCV genotypes 2 and 3 and for
atleast48weeks inthoseinfectedwith HCVgenotype1
(2). Retreatment of poor responders requires longer
durations of therapy, although the optimal duration is
not yet determined. Study durations for peg-IFN or
CIFN in non-responders and relapsers have ranged
from 24 to 72 weeks (108, 110, 112, 114–117).
Long-term maintenance therapy with IFN may
prevent relapse in treatment-resistant patients. Small
studies showed that this long-term treatment strategy
can maintain biochemical and virological responses
and prevent liver histological progression in patients
with an initial partial response to IFN therapy (118,
119). In one maintenance study, 53 patients who had
normalized ALT values but positive HCV RNA titres
after 6 months of IFN-a-2b 5MU three times weekly
were randomly assigned to continue a reduced dose of
IFN 3MU three times weekly or stop therapy (119).
During the initial antiviral treatment, signiﬁcant re-
ductions in serum ALT levels, viral load and hepatic
inﬂammation were noted (Po0.05 vs. baseline for
all measures). These improvements were sustained in
patients receiving maintenance therapy. In contrast,
serum ALT, HCV RNA titres and hepatic inﬂamma-
tion returned to baseline values after IFN withdrawal,
and signiﬁcant increases in the mean hepatic inﬂam-
matory scores (P=0.004 vs. maintenance group) and
worsening hepatic histology per Knodell scoring were
seen in patients not receiving long-term therapy
(Po0.01 vs. maintenance group) (119).
Several trials are assessing the efﬁcacy of peg-IFN
alone or with RBVas maintenance therapy for chronic
hepatitis C (120). The ongoing HALT-C trial is de-
signed to determine the efﬁcacy and safety of low-dose
peg-IFN-a-2a 90mg/week for 3.5 years in chronic
hepatitis C patients with bridging ﬁbrosis or cirrhosis
and persistent viraemia despite previous IFN therapy
(121). The results of such trials should clarify the role
of long-term IFN therapy in difﬁcult-to-treat patients
with chronic hepatitis C.
Drugs in development include small molecules such
as the protease inhibitor, polymerase inhibitor and
toll-like receptor drug classes. While many of these
drugs seem to hold promise as either a primary or an
adjunctive treatment for patients with chronic hepati-
tis C, they are years from market and their safety and
efﬁcacy are uncertain in difﬁcult-to-treat patients
(122). In the meantime, the IFNs will continue to
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Liver cirrhosis (n = 16)
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HCV genotype 1 (n = 41)
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Fig. 2. Sustained virological response per baseline viral and
patient characteristics. [Reprinted from Journal of Hepatology,
Cornberg M et al. ‘Treatment with daily consensus interferon
(CIFN) plus ribavirin in non-responder patients with chronic
hepatitis C: a randomized open-label pilot study.’ 2006; 44: 296.
With permission from the European Association for the Study of
the Liver (110).]
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therapy, retreatment and maintenance therapy.
Predicting treatment response in hepatitis C virus
Achieving viral negativity by week 12 of therapy is
highly predictive of SVR (9). In a retrospective analy-
sis, the SVR rate at 72 weeks was 67% among adults
with chronic hepatitis C who achieved early virological
response with peg-IFN-a-2a and RBV at week 12
(HCV RNA negative or 2 log decrease) (123). In
another study, the SVR rate was only 3% among those
who did not show a 2-log decline or achieve undetect-
able HCV RNA at week 12 (9). Therefore, adequate
monitoring of patients is important throughout ther-
apy as it allows identiﬁcation of patients with inade-
quate treatment response who may beneﬁt from early
introduction of alternative therapies.
Methods that evaluate potential treatment out-
comes could help determine the most appropriate
course of HCV therapy. Hayashida et al. (124) devel-
oped a pretreatment predictive algorithm based on
liver messenger RNA expression proﬁles rather than
viral factors. In this validation study, the algorithm
accurately predicted sustained/transient response and
non-response rates of 97 and 86% (Po0.00001),
respectively, with IFN monotherapy and 97%
(Po0.0001) and 87% (Po0.05), respectively, with
combination antiviral therapy.
While this algorithm may be useful in initially
tailoring antiviral therapy, its utility is limited to the
academic setting. In contrast, modelling HCV kinetics
within the ﬁrst few weeks of IFN therapy is used in the
ambulatory care setting and is key to maximizing
individual patient outcomes (125). Terrault et al.
(126) reported that the probability of a non-sustained
response increases as the values for viral load and
log10 decline in viral load move further away from
designated thresholds. Similar ﬁndings have been
documented by other studies, and hence a o2-log10
decline in HCV RNAat12 weeks ishighly predictive of
a poor response to any combinations of antiviral
therapy (9, 25). Given available data and the impor-
tance of predicting response to antiviral treatment, the
National Institutes of Health, in the 2002 Consensus
Statement on Hepatitis C Management, recommended
that only patients exhibiting at least a 2-log10 decline
in HCV RNA after 12 weeks of combination therapy
should continue long-term treatment (2).
Although the 12-week stopping rule is used to guide
therapy, measures of absolute viral load and log
decline in viral load earlier in the course of HCV
therapy may more accurately predict an SVR as well as
a non-response. In a study of 351 HCV-infected
patients receiving standard treatment with IFN plus
RBV, a viral load 4100000IU/mL after 4 weeks of
treatment and a viral load 410000IU/mL or a
o2log10 decline after 8 and 12 weeks had a negative
predictive value 495% for a non-SVR (Table 4)
(126). At these thresholds, the negative predictive
value remained 495%, regardless of HCV genotype.
Therefore, stopping therapy at 4 weeks after a negative
viral response may help to avoid treatment-related
adverse events and allow earlier re-evaluation of
retreatment options.
Viral kinetics can accurately predict treatment re-
sponse; however, questions about when to assess
response remain. Intuitively, treatment earlier rather
than later is desirable. Prediction of non-response is
possible after a single dose of IFN in patients infected
with HCV (28, 127). Carlsson et al. (127) noted that
patients achieving SVR with standard IFN 3MU plus
RBV had a 79% decline in HCV RNA levels following
the ﬁrst IFN dose. Similarly, in a study by Jessner et al.
(28) in 22 patients with chronic HCV genotype 1, a
change inviral load of 41.4log10 24h after treatment
with IFN-a-2a 9MU had a 100% speciﬁcity in pre-
dicting an SVR after 1 year of combination antiviral
treatment and a 100% sensitivity and 81% speciﬁcity
for a non-response prediction.
In contrast, 24-h measures of viral load after admin-
istration of peg-IFN-a-2a are not predictive of treat-
ment outcomes. Pegylation of IFN changes the drug’s
pharmacokinetics, and maximum plasma concentra-
tions persist over a longer period, half-life is extended
and clearance is reduced (128, 129). Thus, 24h is
insufﬁcient when evaluating treatment response with
peg-IFN; however, a period of 2 weeks is an effective
time to assess antiviral responsiveness in treatment-
naı ¨ve patients receiving peg-IFN regimens (130). Ou-
zan et al. (130) administered peg-IFN-a-2a 180mg/
week plus RBV 1g/week to 20 treatment-naı ¨ve pa-
tients infected with HCV genotype 1. They noted that
a viral load decline 41.39log10copies/mL at week 2
was associated with a positive predictive value of 91%
and a negative predictive value of 89%. After 4 weeks
of treatment, the negative predictive value increased to
100% with a viral drop threshold of 2.81log10copies/
mL. Findings from a study by Carlsson et al. (25)
suggest that treatment outcomes can be predicted even
earlier in the treatment course. After 1 week of peg-
IFN-a-2a 180mg/week in patients with HCV genotype
non-1, a 2-log10copies/mL decline in HCV RNA levels
was associated with an 89% positive predictive value
for SVR. In this investigation, the negative predictive
value of a 2-log10 decline in viral load was only 43% at
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treatment (25).
A retrospective analysis evaluated whether early
declines in HCV RNAwould predict treatment efﬁcacy
of CIFN (131). In the analysis, two trials of CIFN 9 or
15mg in treatment-naı ¨ve patients or non-responders/
relapsers were included for evaluation. Early declines
in viral RNA were associated with SVR in treatment-
naı ¨ve patients (Fig. 3) (131). Measures of viral load
were unavailable until week 8 for the retreatment
group; however, patients who experienced SVR
responded early in the treatment course, as 88% of
responders had undetectable HCV RNA levels by week
8 and 95% had cleared the virus by week 16. In this
analysis, 80% of sustained responders, including
treatment-naı ¨ve and retreatment patients, had unde-
tectable levels of virus by week 8. This percentage
increased to 95% by week 12 in treatment-naı ¨ve
patients and by week 16 in retreatment patients (131).
Based on available data, patients with early HCV RNA
clearance are more likely to experience SVR than
patients exhibiting later declines in viral load. Thus,
early assessment of viral kinetics may help to predict
sustained response to IFN therapy and determine the
value of continuing therapy sooner, rather than later,
in the treatment course.
Conclusions
Multiple factors related to HCV may negatively affect
treatment outcomes and complicate management of
patients with hepatitis C. Unfortunately, because most
of these factors cannot be modiﬁed, a signiﬁcant num-
ber of patients will not respond to antiviral therapy or
will relapse following treatment withdrawal. Recogniz-
ing viral, hepatic and demographical factors that foster
treatment resistance in HCV infection can alert clin-
icians to the potential for poor long-term outcomes
with IFN plus RBV treatment. Similarly, methods (e.g.
measuring viral load early in the treatment course) may
help to predict poor response and determine the need
for treatment modiﬁcations.
Table 4. Positive and negative values, clinical sensitivity and speciﬁcity of viral load, and log-decline predictors of sustained and
non-sustained virological response
Week Prediction rules
Negative predictive valuew Positive predictive valuez Clinical speciﬁcity‰ Clinical sensitivityz
% (95% CI) n % (95% CI) n % (95% CI) % (95% CI)
4 100000IU/mL 96.6 (88.3–99.6) 57/59 55.5 (49.2–61.7) 142/256 33.3 (26.3–40.9) 98.6 (95.1–99.8)
1-log declinek or
o1000IU/mL
94.0 (86.7–98.0) 79/84 60.2 (53.5–66.5) 139/231 46.2 (38.6–54.0) 96.5 (92.1–98.9)
8 10000IU/mL 98.7 (92.8–100.0) 74/75 66.5 (59.6–73.0) 135/203 52.1 (43.6–60.6) 99.3 (96.0–100)
2-log decline or
o1000IU/mL
97.5 (91.2–99.7) 77/79 67.3 (60.3–73.8) 134/199 54.2 (45.7–62.6) 98.5 (94.8–99.8)
12 10000IU/mL 97.1 (90.1–99.7) 68/70 59.1 (52.6–65.3) 143/242 40.7 (33.2–48.6) 98.6 (95.1–99.8)
2-log decline or
o1000IU/mL
97.4 (90.9–99.7) 75/77 60.9 (54.3–67.1) 143/235 44.9 (37.2–52.8) 98.6 (95.1–99.8)
[Adapted with permission of Blackwell Publishing Ltd from Journal of Viral Hepatitis. 2005; 12: 465–472. r 2005.]
All patients included.
wPercentage of patients with actual non-sustained virological response of those who were predicted to have non-sustained virological response
(i.e. HCV RNA positive at 6 months post-therapy).
zPercentage of patients with actual sustained virological response of those who were predicted to have sustained virological response (i.e., HCV RNA
negative at 6 months post-therapy).
‰Percentage of patients correctly predicted by the test as having non-sustained virological response.
zPercentage of patients correctly predicted to have a sustained virological response of all patients having sustained virological response.
kNone of the log decline rules at week 4 attained a negative predictive value of 495%. The 1-log decline had the highest negative predictive value.
CI, conﬁdence interval.
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Fig. 3. Percentage of sustained responders who showed ﬁrst
viral response by week. [Reprinted with permission of John
Wiley & Sons Inc., Hepatology, 1998; 28, 1411–1415. r 1998
American Association for the study of Liver Diseases.]
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Kemmer and Neff Difﬁcult-to-treat HCV patientsTherapeutic options for treatment-resistant patients
are limited, but retreatment with peg-IFN plus RBVor
CIFN can produce SVR in complicated HCV infec-
tions. Additionally, preliminary ﬁndings suggest lim-
ited beneﬁts of maintenance IFN therapy in patients
remaining HCV RNA positive with antiviral therapy.
Although potentially beneﬁcial, the cost, safety and
risk of non-compliance could limit this approach.
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